



ASX Announcement

22 November 2024

Cambium Bio Limited Announces Board Changes

Sydney, Australia; 22 November 2024: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium or Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce changes to its Board of Directors.

Appointment of A/Prof. Chandra Bala

Clinical A/Prof Chandra Bala, MBBS, PhD, will join Cambium's Board effective 22 November 2024. A world-renowned ophthalmologist, A/Prof Bala brings extensive expertise in cataract, cornea, and refractive surgery. His distinguished career spans academia, research, and clinical practice, with numerous publications in international peer-reviewed journals and significant involvement in Phase 2 to 4 ophthalmic clinical trials. As senior partner at PersonalEyes, a leading ophthalmic group operating 12 clinics across Australia, and in his role as a cornea surgeon at Macquarie University Hospital, A/Prof Bala demonstrates a commitment to excellence in patient care. His dedication to advancing ophthalmic medicine through translational research, teaching, and community service aligns perfectly with Cambium's mission to innovate in the field of regenerative medicine.



Cambium Bio CEO, **Karolis Rosickas**, commented: "We are delighted to welcome A/Prof Chandra Bala to Cambium Bio's Board of Directors. A/Prof. Bala's extensive clinical expertise in ophthalmology, particularly in treating ocular surface diseases, will be instrumental as we advance our Phase 3 trials for dry eye disease. His insights will be invaluable in guiding our clinical strategy and ensuring that Elate Ocular meets the needs of patients and clinicians alike. We look forward to leveraging A/Prof. Bala's experience to support Cambium's mission of bringing innovative therapies to market in the US, Australia, and beyond."

A/Prof. Chandra Bala stated: "I am honoured to join the Board of Cambium Bio at this pivotal time in the company's development. Dry eye disease represents a significant and growing unmet medical need globally, affecting millions of patients. Having treated numerous individuals struggling with this condition, I am excited by the potential of Elate Ocular to address the

limitations of current therapies. Its promising efficacy profile and novel mechanism of action position it well to potentially transform patient care. I look forward to working closely with the Board and executive team to guide Elate Ocular through its critical Phase 3 trials and towards regulatory approval, with the ultimate goal of improving outcomes for patients worldwide."

Retirement of Prof. Graham Vesey

Prof. Graham Vesey will retire from the Board of Directors effective as of 22 November 2024. The Board would like to thank Dr. Vesey for his contribution to the Company since its founding in 2007 and subsequent listing on the ASX in 2013.

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

- ENDS -

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Helen Leung
Corporate Secretary
info@cambium.bio
1 300 995 098